Claret Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Claret Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$240K	Sell	1,425 -498	-26%	-$73.9K	0.03%	202
2026 Q1	$253K	Sell	1,923 -8	-0.4%	-$1.06K	0.03%	242
2025 Q4	$274K	Buy	1,931 +103	+6%	+$14.9K	0.03%	210
2025 Q3	$257K	Sell	1,828 -26	-1%	-$3.52K	0.03%	234
2025 Q2	$233K	Buy	+1,854	New	+$213K	0.03%	320
2025 Q1	–	Sell	-1,494	Closed	-$204K	–	334
2024 Q4	$204K	Buy	+1,494	New	+$185K	0.03%	287
2024 Q2	–	Sell	-1,451	Closed	-$200K	–	281
2024 Q1	$200K	Sell	1,451 -114	-7%	-$15.6K	0.03%	200
2023 Q4	$206K	Buy	+1,565	New	+$180K	0.04%	169

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Claret Asset Management's NBIX Position: Q2 2026 in Review

Claret Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 26% in Q2 2026, selling an estimated $73.9K and leaving 1,425 shares worth $240K. The position accounts for 0.03% of the portfolio, ranked #202.

Claret Asset Management first reported a position in NBIX in Q4 2023 and has held it in 8 quarters since. The position peaked at $274K in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Claret Asset Management held 1,425 shares of Neurocrine Biosciences worth $240K as of Q2 2026.
Claret Asset Management sold 498 Neurocrine Biosciences shares in Q2 2026, an estimated $73.9K.
Neurocrine Biosciences made up 0.03% of Claret Asset Management's portfolio in Q2 2026, its #202 holding.
Claret Asset Management first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 8 quarters since.
Claret Asset Management's Neurocrine Biosciences position peaked at $274K in Q4 2025.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.